Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Of biological response modifier (BRM), alpha IFN in 11 cases of NSCLC with RR of 9% and MST of 14 months, IL-2 and LAK cell treatment in 11 cases with RR of 9% and MST of 18 months are reported.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP224595.RA9Xx7ywR2eSVWXKIufiYX6yaWRA3yTequRtGE_Pfuo4c130_assertion description "[Of biological response modifier (BRM), alpha IFN in 11 cases of NSCLC with RR of 9% and MST of 14 months, IL-2 and LAK cell treatment in 11 cases with RR of 9% and MST of 18 months are reported.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP224595.RA9Xx7ywR2eSVWXKIufiYX6yaWRA3yTequRtGE_Pfuo4c130_provenance.
• NP353125.RAyAksF238axzvoaYvjw-tFjsTDJgHfj06FlGXJnpCt1o130_assertion description "[Of biological response modifier (BRM), alpha IFN in 11 cases of NSCLC with RR of 9% and MST of 14 months, IL-2 and LAK cell treatment in 11 cases with RR of 9% and MST of 18 months are reported.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP353125.RAyAksF238axzvoaYvjw-tFjsTDJgHfj06FlGXJnpCt1o130_provenance.
• NP530185.RAz44wgFIVLwTA8A-z6w2_D-bb2e7PJvbMZ5ZxcG_2Ing130_assertion description "[Of biological response modifier (BRM), alpha IFN in 11 cases of NSCLC with RR of 9% and MST of 14 months, IL-2 and LAK cell treatment in 11 cases with RR of 9% and MST of 18 months are reported.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP530185.RAz44wgFIVLwTA8A-z6w2_D-bb2e7PJvbMZ5ZxcG_2Ing130_provenance.
• NP476310.RAVs0qWnQLPHPK68WFL5zBzIys-HH8yeXtFTxr7VhK2Sw130_assertion description "[Of biological response modifier (BRM), alpha IFN in 11 cases of NSCLC with RR of 9% and MST of 14 months, IL-2 and LAK cell treatment in 11 cases with RR of 9% and MST of 18 months are reported.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP476310.RAVs0qWnQLPHPK68WFL5zBzIys-HH8yeXtFTxr7VhK2Sw130_provenance.
• NP792933.RAX5OYuBuNZYOm5pf0JLcO0nryrZciRdKIAuq2vspn3Tw130_assertion description "[Of biological response modifier (BRM), alpha IFN in 11 cases of NSCLC with RR of 9% and MST of 14 months, IL-2 and LAK cell treatment in 11 cases with RR of 9% and MST of 18 months are reported.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP792933.RAX5OYuBuNZYOm5pf0JLcO0nryrZciRdKIAuq2vspn3Tw130_provenance.
• assertion description "[Of biological response modifier (BRM), alpha IFN in 11 cases of NSCLC with RR of 9% and MST of 14 months, IL-2 and LAK cell treatment in 11 cases with RR of 9% and MST of 18 months are reported.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Of biological response modifier (BRM), alpha IFN in 11 cases of NSCLC with RR of 9% and MST of 14 months, IL-2 and LAK cell treatment in 11 cases with RR of 9% and MST of 18 months are reported.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Of biological response modifier (BRM), alpha IFN in 11 cases of NSCLC with RR of 9% and MST of 14 months, IL-2 and LAK cell treatment in 11 cases with RR of 9% and MST of 18 months are reported.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Of biological response modifier (BRM), alpha IFN in 11 cases of NSCLC with RR of 9% and MST of 14 months, IL-2 and LAK cell treatment in 11 cases with RR of 9% and MST of 18 months are reported.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Of biological response modifier (BRM), alpha IFN in 11 cases of NSCLC with RR of 9% and MST of 14 months, IL-2 and LAK cell treatment in 11 cases with RR of 9% and MST of 18 months are reported.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Of biological response modifier (BRM), alpha IFN in 11 cases of NSCLC with RR of 9% and MST of 14 months, IL-2 and LAK cell treatment in 11 cases with RR of 9% and MST of 18 months are reported.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP558796.RAvMEyn_r-UIzGA1kaxKkzkt5HZNa-y2yuhDHB8ocQjeo130_assertion description "[Of biological response modifier (BRM), alpha IFN in 11 cases of NSCLC with RR of 9% and MST of 14 months, IL-2 and LAK cell treatment in 11 cases with RR of 9% and MST of 18 months are reported.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP558796.RAvMEyn_r-UIzGA1kaxKkzkt5HZNa-y2yuhDHB8ocQjeo130_provenance.
• NP568037.RAlZWP9nziUv-R1H4AZp89xc0rtRq7NRSTK9mxqeaYTUo130_assertion description "[Of biological response modifier (BRM), alpha IFN in 11 cases of NSCLC with RR of 9% and MST of 14 months, IL-2 and LAK cell treatment in 11 cases with RR of 9% and MST of 18 months are reported.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP568037.RAlZWP9nziUv-R1H4AZp89xc0rtRq7NRSTK9mxqeaYTUo130_provenance.
• NP1405596.RAbQtVVjMK6ZiwJ3fU2qczBO1vQzRGkjL4YM8iiSvYUDg130_assertion description "[Of biological response modifier (BRM), alpha IFN in 11 cases of NSCLC with RR of 9% and MST of 14 months, IL-2 and LAK cell treatment in 11 cases with RR of 9% and MST of 18 months are reported.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1405596.RAbQtVVjMK6ZiwJ3fU2qczBO1vQzRGkjL4YM8iiSvYUDg130_provenance.
• NP477502.RAhqhL9Tww1l9wXucBs30NwbfSlNSI9j6B2niyfyA8Z4c130_assertion description "[Of biological response modifier (BRM), alpha IFN in 11 cases of NSCLC with RR of 9% and MST of 14 months, IL-2 and LAK cell treatment in 11 cases with RR of 9% and MST of 18 months are reported.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP477502.RAhqhL9Tww1l9wXucBs30NwbfSlNSI9j6B2niyfyA8Z4c130_provenance.
• NP1405598.RAtcfqkaG9c7TS89I5CjNnVITPtUmvzsGOzfTGRuNJQ2I130_assertion description "[Of biological response modifier (BRM), alpha IFN in 11 cases of NSCLC with RR of 9% and MST of 14 months, IL-2 and LAK cell treatment in 11 cases with RR of 9% and MST of 18 months are reported.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1405598.RAtcfqkaG9c7TS89I5CjNnVITPtUmvzsGOzfTGRuNJQ2I130_provenance.
• NP1405599.RAngbi2adoumtQG1TfPV_B1-frGYH2nVmwbCrLDF2nTNM130_assertion description "[Of biological response modifier (BRM), alpha IFN in 11 cases of NSCLC with RR of 9% and MST of 14 months, IL-2 and LAK cell treatment in 11 cases with RR of 9% and MST of 18 months are reported.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1405599.RAngbi2adoumtQG1TfPV_B1-frGYH2nVmwbCrLDF2nTNM130_provenance.
• NP1405597.RAEDSh43N7_2L055D-hVkKnEeafH93VMYun2-HzdJvOyk130_assertion description "[Of biological response modifier (BRM), alpha IFN in 11 cases of NSCLC with RR of 9% and MST of 14 months, IL-2 and LAK cell treatment in 11 cases with RR of 9% and MST of 18 months are reported.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1405597.RAEDSh43N7_2L055D-hVkKnEeafH93VMYun2-HzdJvOyk130_provenance.
• NP1405602.RALv6urcTDWYF38cYop6pBkE-j_Z_dRL8R5jegtOlI4To130_assertion description "[Of biological response modifier (BRM), alpha IFN in 11 cases of NSCLC with RR of 9% and MST of 14 months, IL-2 and LAK cell treatment in 11 cases with RR of 9% and MST of 18 months are reported.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1405602.RALv6urcTDWYF38cYop6pBkE-j_Z_dRL8R5jegtOlI4To130_provenance.
• NP916771.RA8zayiSYzmliiSUUp2Bje-0UHYoaBTGrB5f0WuAmeRFY130_assertion description "[Of biological response modifier (BRM), alpha IFN in 11 cases of NSCLC with RR of 9% and MST of 14 months, IL-2 and LAK cell treatment in 11 cases with RR of 9% and MST of 18 months are reported.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP916771.RA8zayiSYzmliiSUUp2Bje-0UHYoaBTGrB5f0WuAmeRFY130_provenance.
• NP1405601.RAzJs3VxzmUCawQrI_0HzyV-a306oUPiYYFngch4CecsQ130_assertion description "[Of biological response modifier (BRM), alpha IFN in 11 cases of NSCLC with RR of 9% and MST of 14 months, IL-2 and LAK cell treatment in 11 cases with RR of 9% and MST of 18 months are reported.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1405601.RAzJs3VxzmUCawQrI_0HzyV-a306oUPiYYFngch4CecsQ130_provenance.